Study: Statins Prevent Cardiovascular Events for Rheumatoid Arthritis

Statins may lead to the same level of cardiovascular benefits for patients with rheumatoid arthritis as other individuals, according to a large clinical trial that was recently published in Arthritis & Rheumatology.
Statins are known to help prevent cardiovascular events in certain high-risk individuals by lowering LDL cholesterol, but it has been unclear whether the medication is safe and effective in patients with inflammatory conditions, such as rheumatoid arthritis. Patients who suffered from this condition are approximately 50% more likely to experience cardiovascular events, such as heart attack and stroke.
To evaluate the drug’s safety and efficacy, investigators designed the Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis (TRACE RA), a multi-center, randomized, double-blind trial comparing the statin atorvastatin with placebo, according to the press release.
The trial included approximately 3000 patients with rheumatoid arthritis who were over 50 years of age or who had rheumatoid arthritis for more than 10 years without clinical atherosclerosis, diabetes, or myopathy. Patients were randomized to receive atorvastatin 40 mg daily or placebo.
At the end of the trial, the study showed that patients taking atorvastatin had significantly lower LDL cholesterol as well as significantly lower levels of C-reactive protein, a marker of inflammation, compared with patients taking placebo. Adverse events in the atorvastatin and placebo groups were similar.
The study authors recommend that patients with rheumatoid arthritis be prescribed statins according to national or local guidelines for managing cardiovascular risk in the general population.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Study results demonstrate superior efficacy and comparable safety for tildrakizumab versus a placebo in patients with psoriatic arthritis.
Treatment for inflammatory bowel disease (IBD) has the best outcomes when patients partner with their medical teams.
Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (vWD) have been among the most common conditions addressed in these practice locations.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.